PubRank

A G Dalgleish

Author PubWeight™ 220.08‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 1985 30.47
2 The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 1986 22.26
3 Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients. Nature 1985 6.65
4 Variable and conserved neutralization antigens of human immunodeficiency virus. Nature 1987 5.29
5 Epitopes of the CD4 antigen and HIV infection. Science 1986 4.50
6 Soluble CD4 blocks the infectivity of diverse strains of HIV and SIV for T cells and monocytes but not for brain and muscle cells. Nature 1989 3.54
7 Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 2004 3.37
8 HIV infection does not require endocytosis of its receptor, CD4. Cell 1988 2.88
9 In vivo cellular tropism of human T-cell leukemia virus type 1. J Virol 1990 2.70
10 Human immunodeficiency virus infection of monocytic and T-lymphocytic cells: receptor modulation and differentiation induced by phorbol ester. Virology 1987 2.30
11 Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer 2001 2.26
12 AIDS pathogenesis: HIV envelope and its interaction with cell proteins. Immunol Today 1990 2.21
13 Serum insulin-like growth factor-1 is not a useful marker of prostate cancer. BJU Int 1999 2.14
14 Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 2002 2.03
15 Tropical spastic paraparesis and human T cell lymphotropic virus type 1 in the United Kingdom. Brain 1989 2.00
16 Human T cell leukaemia/lymphoma virus and blood donation. BMJ 1993 1.79
17 The use of 7-amino actinomycin D in identifying apoptosis: simplicity of use and broad spectrum of application compared with other techniques. Blood 1996 1.52
18 Screening for prolonged incubation of HTLV-I infection in British and Jamaican relatives of British patients with tropical spastic paraparesis. BMJ 1990 1.45
19 Retinoids cause apoptosis in pancreatic cancer cells via activation of RAR-gamma and altered expression of Bcl-2/Bax. Br J Cancer 2002 1.44
20 The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. Eur J Cancer 2000 1.43
21 Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br J Cancer 2004 1.43
22 Investigator-initiated trials of targeted oncology agents: why independent research is at risk? Ann Oncol 2010 1.41
23 Primary non-Hodgkin's lymphoma of the thyroid with bone marrow infiltration at presentation. Clin Oncol (R Coll Radiol) 1995 1.41
24 The gp120 envelope of HIV-1 binds peptides in a similar manner to human leukocyte antigens. AIDS 1995 1.38
25 Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br J Cancer 2009 1.35
26 Inactivation of HIV by nonoxynol-9. Lancet 1988 1.30
27 Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells. Clin Exp Immunol 2002 1.30
28 HTLV-III serology distinguishes atypical and endemic Kaposi's sarcoma in Africa. Lancet 1985 1.25
29 CC-3052: a water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production. J Immunol 1998 1.20
30 HIV envelope glycoprotein, antigen specific T-cell responses, and soluble CD4. Lancet 1990 1.16
31 Seven genomic subtypes of chronic fatigue syndrome/myalgic encephalomyelitis: a detailed analysis of gene networks and clinical phenotypes. J Clin Pathol 2007 1.14
32 Priming of human CD4+ antigen-specific T cells to undergo apoptosis by HIV-infected monocytes. A two-step mechanism involving the gp120 molecule. J Clin Invest 1997 1.14
33 Concurrent hydatid disease and cryptococcosis in a 16-year-old girl. Med J Aust 1981 1.11
34 Review article: immune suppression and colorectal cancer. Aliment Pharmacol Ther 2006 1.09
35 Antigen test versus reverse transcriptase assay for detecting HIV. Lancet 1987 1.09
36 Reduction in cytokine production in colorectal cancer patients: association with stage and reversal by resection. Br J Cancer 2000 1.08
37 Dendritic cells infected in vitro with human T cell leukaemia/lymphoma virus type-1 (HTLV-1); enhanced lymphocytic proliferation and tropical spastic paraparesis. Clin Exp Immunol 1993 1.08
38 Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma. Br J Dermatol 2007 1.08
39 The relevance of HIV env/CD4 interactions to the pathogenesis of acquired immune deficiency syndrome. J Acquir Immune Defic Syndr 1989 1.07
40 Cytokines and soluble receptor changes in the transition from primary to early chronic HIV type 1 infection. AIDS Res Hum Retroviruses 1996 1.07
41 Human retroviruses and paediatric disease. Arch Dis Child 1987 1.06
42 Lymphokine-activated killer cell activity in rheumatoid arthritis. Clin Exp Immunol 1987 1.05
43 Isolation of retroviruses from two patients with "common variable" hypogammaglobulinaemia. Lancet 1986 1.04
44 Heat shock proteins refine the danger theory. Immunology 2000 1.04
45 Inhibition of HIV replication in vitro by fusidic acid. Lancet 1987 1.03
46 Coeliac disease presenting with cerebellar degeneration. Postgrad Med J 1991 1.03
47 Thalidomide as an emerging immunotherapeutic agent. Immunol Today 1999 1.02
48 Immunotherapeutic and antitumour potential of thalidomide analogues. Expert Opin Biol Ther 2001 1.02
49 Differential and antagonistic effects of 9-cis-retinoic acid and vitamin D analogues on pancreatic cancer cells in vitro. Br J Cancer 2000 1.01
50 Phosphonoformate (foscarnet): a pilot study in AIDS and AIDS related complex. AIDS 1987 1.01
51 Improving the efficacy of cancer immunotherapy. Eur J Cancer 2009 1.01
52 Abnormal intracellular IL-2 and interferon-gamma (IFN-gamma) production as HIV-1-assocated markers of immune dysfunction. Clin Exp Immunol 1998 1.00
53 Possible improved survival of patients with stage IV AJCC melanoma receiving SRL 172 immunotherapy: correlation with induction of increased levels of intracellular interleukin-2 in peripheral blood lymphocytes. Ann Oncol 1999 1.00
54 Immunotherapy of advanced prostate cancer: a phase I/II trial using Mycobacterium vaccae (SRL172). Br J Urol 1998 1.00
55 A phase II study of continuous-infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer. Br J Cancer 1996 0.99
56 Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignancies. Eur J Cancer 2006 0.98
57 Characteristics and growth patterns of human peritoneal mesothelial cells: comparison between advanced epithelial ovarian cancer and non-ovarian cancer sources. J Soc Gynecol Investig 2000 0.98
58 Angiogenesis as a biomarker and target in cancer chemoprevention. Lancet Oncol 2001 0.97
59 Studies in healthy human T-cell-leukemia lymphoma virus (HTLV-I) carriers from the Caribbean. Int J Cancer 1986 0.97
60 The interleukins in acquired disease. Clin Exp Immunol 1988 0.96
61 The T4 glycoprotein is a cell-surface receptor for the AIDS virus. Cold Spring Harb Symp Quant Biol 1986 0.95
62 Human immunodeficiency viruses: neutralization and receptors. J Acquir Immune Defic Syndr 1988 0.94
63 Interleukin-10-induced HIV-1 expression is mediated by induction of both membrane-bound tumour necrosis factor (TNF)-alpha and TNF receptor type 1 in a promonocytic cell line. AIDS 1996 0.93
64 Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanoma. Br J Dermatol 2008 0.92
65 Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs). Br J Cancer 2009 0.92
66 Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells. Br J Cancer 2011 0.91
67 Human tumour and dendritic cell hybrids generated by electrofusion: potential for cancer vaccines. Biochim Biophys Acta 2000 0.91
68 The correlation between colorectal cancer rates of proliferation and apoptosis and systemic cytokine levels; plus their influence upon survival. Br J Cancer 2006 0.91
69 CD40 ligation for immunotherapy of solid tumours. J Immunol Methods 2001 0.90
70 Reduced expression of interleukin-2 receptors in hypogammaglobulinaemia: a possible cause of higher cancer incidence. Lancet 1986 0.90
71 A search for retrovirus infection in systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis 1988 0.90
72 Role of flanking variable sequences in antigenicity of consensus regions of HIV gp120 for recognition by specific human T helper clones. Eur J Immunol 1993 0.90
73 Bladder and prostate cancer screening for human papillomavirus by polymerase chain reaction: conflicting results using different annealing temperatures. Br J Biomed Sci 1993 0.89
74 Abnormal cytokine profiles in patients with idiopathic dilated cardiomyopathy and their asymptomatic relatives. Heart 1996 0.88
75 Infection of B lymphocytes by the human immunodeficiency virus and their susceptibility to cytotoxic cells. Eur J Immunol 1988 0.88
76 1-(3-cyano-2,3-dideoxy-beta-D-erythro-pentofuranosyl)thymine (cyanothymidine): synthesis and antiviral evaluation against human immunodeficiency virus. J Med Chem 1989 0.87
77 A double-blind placebo-controlled phase II trial of thalidomide in asymptomatic HIV-positive patients: clinical tolerance and effect on activation markers and cytokines. AIDS Res Hum Retroviruses 1997 0.87
78 HTLV-I infection and neurological disease in Rio de Janeiro. J Neurol Neurosurg Psychiatry 1992 0.87
79 Treatment patterns, outcomes, and resource utilization of patients with metastatic melanoma in the U.K.: the MELODY study. Br J Dermatol 2014 0.87
80 Allogeneic murine melanoma cell vaccine: a model for the development of human allogeneic cancer vaccine. Melanoma Res 1996 0.86
81 Quantitation of HIV-1 activity in tissue culture supernatants: effects of culture condition on syncytial assays and virus production. J Virol Methods 1989 0.86
82 Eosinophilic folliculitis occurring after bone marrow autograft in a patient with non-Hodgkin's lymphoma. Cancer 1994 0.85
83 Retinoic acid enhances the cytotoxic effects of gemcitabine and cisplatin in pancreatic adenocarcinoma cells. Pancreas 2001 0.85
84 Immune reconstitution in HAART-treated children with AIDS. Highly Active Anti-Retroviral Therapy. Lancet 1998 0.85
85 Bleomycin pulmonary toxicity: its relationship to renal dysfunction. Med Pediatr Oncol 1984 0.85
86 Anti-tumour activity against B16-F10 melanoma with a GM-CSF secreting allogeneic tumour cell vaccine. Gene Ther 1999 0.85
87 Phase I study of ONO-4007, a synthetic analogue of the lipid A moiety of bacterial lipopolysaccharide. Clin Cancer Res 2000 0.85
88 Repertoire breadth of human CD4+ T cells specific for HIV gp120 and p66 (primary antigens) or for PPD and tetanus toxoid (secondary antigens) Hum Immunol 1998 0.85
89 Allogeneic whole-tumour cell vaccination in the rat model of prostate cancer. BJU Int 2000 0.84
90 Role of CD4 in the penetration of cells by HIV. Adv Exp Med Biol 1991 0.84
91 Antibody-dependent cell-mediated cytotoxicity: comparison between HTLV-I and HIV-1 assays. AIDS 1988 0.84
92 Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo. Prostate 2011 0.84
93 Retroviruses in rheumatoid arthritis. Ann Rheum Dis 1986 0.83
94 Cellular immunology of HIV-infection. Clin Exp Immunol 1988 0.83
95 Dendritic cells are potent antigen-presenting cells for in vitro induction of primary human CD4+ T-cell lines specific for HIV gp120. J Acquir Immune Defic Syndr 1994 0.83
96 Tumour necrosis factor (TNF) and TNF-related molecules in HIV-1+ individuals: relationship with in vitro Th1/Th2-type response. Clin Exp Immunol 1998 0.83
97 Evaluation of hypochlorite-releasing disinfectants against the human immunodeficiency virus (HIV). J Hosp Infect 1990 0.83
98 A randomized phase II trial of SRL172 (Mycobacterium vaccae) +/- low-dose interleukin-2 in the treatment of metastatic malignant melanoma. Melanoma Res 2003 0.82
99 Thalidomide analogue CC-3052 reduces HIV+ neutrophil apoptosis in vitro. Clin Exp Immunol 2000 0.82
100 Anti-CD4 autoantibodies and screening for anti-idiotypic antibodies to anti-CD4 monoclonal antibodies in HIV-seropositive people. AIDS 1990 0.82
101 Potential applications of gene therapy in the patient with cancer. Drugs Aging 2000 0.81
102 Kaposi's sarcoma. Br J Cancer 1991 0.81
103 The role of immunotherapy for urological tumours. Br J Urol 1997 0.81
104 A proposed molecular model for the carboxy terminus of HIV-1 gp120 showing structural features consistent with the presence of a T-cell alloepitope. Mol Aspects Med 1991 0.81
105 The thalidomide analogue CC-3052 inhibits HIV-1 and tumour necrosis factor-alpha (TNF-alpha) expression in acutely and chronically infected cells in vitro. Clin Exp Immunol 2000 0.81
106 Coxsackie B and adenovirus receptor, integrin and major histocompatibility complex class I expression in human prostate cancer cell lines: implications for gene therapy strategies. Prostate Cancer Prostatic Dis 2003 0.81
107 The role of host immune responses in determining the outcome of HIV infection. Immunol Today 1996 0.81
108 Antiviral strategies and vaccines against HTLV III/LAV. J R Coll Physicians Lond 1986 0.81
109 Immunomodulatory agents: the cytokines. Eur J Cancer 1994 0.81
110 Tumour markers in malignancies. CA19.9 is useful in several cancers. BMJ 2000 0.80
111 Inhibition of p38 MAP kinase during cellular activation results in IFN-gamma-dependent augmentation of IL-12 production by human monocytes/macrophages. Clin Exp Immunol 2001 0.80
112 How immunotherapy can enhance the response to other modalities and improve outcome and quality of life. J BUON 2009 0.80
113 A novel murine model of allogeneic vaccination against prostate cancer. Cancer Immunol Immunother 2007 0.80
114 Alloactivated cytotoxic T cells recognize the carboxy-terminal domain of human immunodeficiency virus-1 gp120 envelope glycoprotein. Eur J Immunol 1993 0.80
115 HTLV-I and neurological disease in South India. Lancet 1989 0.80
116 Elevated serum levels of soluble interleukin-2 receptor, neopterin and beta-2-microglobulin in idiopathic dilated cardiomyopathy: relation to disease severity and autoimmune pathogenesis. Eur J Heart Fail 2001 0.80
117 Supernatants derived from chemotherapy-treated cancer cell lines can modify angiogenesis. Br J Cancer 2012 0.80
118 The effect of colorectal cancer upon host peripheral immune cell function. Colorectal Dis 2009 0.79
119 Central nervous system echovirus infection in Bruton's X-linked hypogammaglobulinemia. Aust N Z J Med 1985 0.79
120 Neopterin concentrations in serum and cerebrospinal fluid in HTLV-I infected individuals. J Neurol 1992 0.79
121 Lack of T cell response to cardiac myosin and a reduced response to PPD in patients with idiopathic dilated cardiomyopathy. J Autoimmun 1997 0.79
122 Evolution, immune response, and cancer. Lancet 2000 0.79
123 Inhibitory activity of HIV envelope gp120 dominates over its antigenicity for human T cells. Clin Exp Immunol 1992 0.79
124 Supernatants from lymphocytes stimulated with Bacillus Calmette-Guerin can modify the antigenicity of tumours and stimulate allogeneic T-cell responses. Br J Cancer 2011 0.79
125 Mycobacterium vaccae (SRL172): a potential immunological adjuvant evaluated in rat prostate cancer. Br J Urol 1998 0.79
126 HIV-induced deletion of antigen-specific T cell function is MHC restricted. Clin Exp Immunol 1992 0.78
127 Changes in dendritic cell subsets in the lymph nodes of rhesus macaques after application of glucocorticoids. Hum Immunol 2001 0.78
128 Normal and SV40 transfected human peritoneal mesothelial cells produce IL-6 and IL-8: implication for gynaecological disease. Clin Exp Immunol 2002 0.78
129 Gene therapy for prostate cancer. Gene Ther 1996 0.77
130 Genetic prodrug activation therapy (GPAT) in two rat prostate models generates an immune bystander effect and can be monitored by magnetic resonance techniques. Gene Ther 2001 0.77
131 The role of hepatitis B virus in the etiology of hepatocellular carcinoma in Australia. Aust N Z J Med 1983 0.77
132 Efficacy of cytokine gene transfection may differ for autologous and allogeneic tumour cell vaccines. Immunology 2001 0.77
133 Oncological applications of gene therapy. Curr Opin Investig Drugs 2000 0.77
134 Cancer biologists hit the road. Molecular genetics of cancer: Second Joint Conference of the American Association for Cancer Research and the European Association for Cancer Research. Oxford, UK, 9-13 September 1997. Cancer gene therapy symposium. London, UK, 23-24 June 1997. Mol Med Today 1997 0.77
135 Comparison of IL-2- and IL-4-transfected B16-F10 cells with a novel oil-microemulsion adjuvant for B16-F10 whole cell tumour vaccine. Gene Ther 1996 0.77
136 Panel of anti-gp120 monoclonal antibodies reacts with same nuclear proteins in uninfected cells as those recognized by autoantibodies from patients with systemic lupus erythematosus. AIDS Res Hum Retroviruses 1994 0.77
137 Gene therapy: recent progress in the clinical oncology arena. Curr Opin Mol Ther 2000 0.77
138 Human retroviruses. Aust N Z J Med 1985 0.77
139 Low CD4 counts rather than superantigenic-like effects account for differences in expressed T-cell receptor (TCR) repertoires between HIV-1 seropositive long-term non-progressors and individuals with progressive disease. Br J Haematol 1998 0.76
140 Refractory hypercalcaemia. Parathyroid adenoma or multiple myeloma? Med J Aust 1984 0.76
141 Idiotype cascades associated with the CD4-HIV glycoprotein 120 interaction: immunization with anti-idiotypic antibodies induces anti-anti-idiotypic responses with anti-CD4 specificity and in vitro neutralizing activity. AIDS Res Hum Retroviruses 2000 0.76
142 Search for a retroviral cause for sarcoidosis: no evidence from peripheral blood studies. Eur Respir J 1991 0.76
143 A viral etiology for Hodgkin's disease? Aust N Z J Med 1986 0.76
144 Anti-idiotypic therapeutic strategies in HIV infection. Mol Cell Biol Hum Dis Ser 1992 0.76
145 Hypertrophic pulmonary osteoarthropathy: response to chemotherapy without documented tumour response. Aust N Z J Med 1983 0.75
146 The gp120 envelope of HIV-1 binds and presents peptides in a similar manner to human leukocyte antigen. AIDS 1999 0.75
147 Thrombophlebitis migrans following co-trimoxazole therapy. Postgrad Med J 1989 0.75
148 Immunotherapy with Mycobacterium vaccae. Lancet 1999 0.75
149 Infection and cancer. Lancet 2001 0.75
150 Adult coeliac disease. Lancet 1996 0.75
151 Absence of GVH diseases in AIDS. J Acquir Immune Defic Syndr 1994 0.75
152 Chemotherapy for solid tumours. BMJ 1995 0.75
153 A unified hypothesis for three cardinal features of HIV immunology: authors' reply. J Acquir Immune Defic Syndr 1991 0.75
154 Is Crohn's disease caused by a lymphotropic virus? J Pediatr Gastroenterol Nutr 1986 0.75
155 Viral burden in AIDS. Nature 1993 0.75
156 HTLV-I/II and T-cell proliferation. Lancet 1985 0.75
157 Proteinase inhibitors. Mol Aspects Med 1991 0.75
158 Vascular endothelium: a potential role in HIV infection and the pathogenesis of Kaposi's sarcoma: observations and speculations. Mol Aspects Med 1991 0.75
159 AIDS, Portugal, and Africa. Lancet 1986 0.75
160 Lacticacidosis of thiamine deficiency. Lancet 1984 0.75
161 Neurosis divisible and SLE. Lancet 1985 0.75
162 Disease regression in malignant melanoma: spontaneous resolution or a result of treatment with antioxidants, green tea, and pineapple cores? A case report. Integr Cancer Ther 2007 0.75
163 The role of herpes simplex virus thymidine kinase in the treatment of solid tumours. Expert Opin Investig Drugs 1999 0.75
164 Comparison of four strategies for tumour vaccination in the B16-F10 melanoma model. Gene Ther 1998 0.75
165 Advances in prostate cancer immunotherapy. Surg Oncol 2002 0.75
166 Chemotherapy against human immunodeficiency virus infection. Mol Aspects Med 1991 0.75
167 Optimisation of a peptide-based indirect ELISA for the detection of antibody in the serum of HIV-1 seropositive patients. J Immunol Methods 1997 0.75
168 Why: gene therapy? Gene Ther 1997 0.75
169 Detection of T cell cytokine production as a tool for monitoring immunotherapy. Dis Markers 2000 0.75
170 Sexual transmission of AIDS. Br J Hosp Med 1985 0.75
171 HIV gp120 plus specific peptides are recognized in a similar manner to specific HLA plus peptide by HLA-restricted antigen-specific T-cell lines. Viral Immunol 2000 0.75
172 Gene therapy for prostate cancer. Semin Oncol 1999 0.75
173 Antiidiotypic responses to immunization with anti-Leu 3a in human immunodeficiency virus-seropositive individuals. J Infect Dis 1991 0.75
174 Neutralization and receptor recognition of human T-lymphotropic retroviruses. Haematol Blood Transfus 1987 0.75
175 Human retroviruses. Blood Rev 1988 0.75
176 Hepatocellular carcinoma associated with hepatitis B in a renal graft recipient. Med J Aust 1983 0.75
177 Heterosexual spread of HIV. Dis Markers 1990 0.75
178 Prospects for vaccination in prostate cancer. Drugs Aging 2000 0.75
179 Acquired immune deficiency syndrome. A prodromal form. Med J Aust 1983 0.75
180 An alternative to 51Cr release assay for measurement of natural killer activity in HIV-infected patients. AIDS 1996 0.75
181 Human immunodeficiency virus and the immunology of infection. Baillieres Clin Obstet Gynaecol 1992 0.75
182 DNA vaccines. Expert Opin Investig Drugs 2000 0.75